Best Practices for Natalizumab Utilization in the Treatment of Multiple Sclerosis This supplement to The American Journal ofManaged Care reviews the clinical and economic burden of multiple sclerosis and summarizes the efficacy and safety of natalizumab. The impact of natalizumab on clinical and economic outcomes is discussed. The role of natalizumab in clinical practice is outlined, with emphasis on selection of appropriate patients for treatment.
Faculty David W. Brandes, MS, MD, FAAN Hope Neurology Knoxville, Tennessee Assistant Clinical Professor, Neurology University of California, Los Angeles Los Angeles, California
Patricia K. Coyle, MD Professor and Acting Chair Department of Neurology Stony Brook University Medical Center and Stony Brook MS Comprehensive Care Center Stony Brook, New York
John Foley, MD Director Rocky Mountain Multiple Sclerosis Clinic Rocky Mountain Neurological Associates Salt Lake City, Utah
Michael W. Pill, PharmD President Gemini Healthcare, LLC Westbrook, Connecticut
Fadia T. Shaya, PhD, MPH Associate Professor University of Maryland School of Pharmacy Baltimore, Maryland
Faculty Disclosures These faculty report relationships with the following organizations:
David W. Brandes, MS, MD, FAAN Consultant/advisory board/honoraria/lectureship: Bayer Biogen Idec EMD Serono Teva
Michael W. Pill, PharmD,and Fadia T. Shaya, PhD, MPH,have nothing to disclose.
This supplement was supported by Biogen Idec Inc.
The contents of this supplement may include information regarding the use of products that may be inconsistent with or outside the approved labeling for these products in the United States. Physicians should note that the use of these products outside current approved labeling is considered experimental and are advised to consult prescribing information for these products.